Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
Bennett JC, Luiten KG, O'Hanlon J, Han PD, McDonald D, Wright T, Wolf CR, Lo NK, Acker Z, Regelbrugge L, McCaffrey KM, Pfau B, Stone J, Schwabe-Fry K, Lockwood CM, Guthrie BL, Gottlieb GS, Englund JA, Uyeki TM, Carone M, Starita LM, Weil AA, Chu HY.
Bennett JC, et al. Among authors: lockwood cm.
Vaccine. 2024 Feb 27;42(6):1332-1341. doi: 10.1016/j.vaccine.2024.01.080. Epub 2024 Feb 1.
Vaccine. 2024.
PMID: 38307746